文献速递产科母胎医学

产前皮质类固醇与双胎新生儿呼吸结局:一项回归断点研究

Antenatal corticosteroids and newborn respiratory outcomes in twins: A regression discontinuity study.
PubMed 文献 · BJOG · 2024-01-14

该研究基于加拿大不列颠哥伦比亚省2008至2018年基于人群的出生登记数据,采用回归断点设计分析2524例双胎妊娠(5035例活产双胎),比较临床指南推荐产前皮质类固醇使用 cutoff(33+6周)前后入院分娩者的新生儿呼吸结局。结果显示34+0周时新生儿呼吸窘迫或院内死亡风险突然升高,对应治疗保护效应(RR 0.69,95%CI 0.53-0.90)。

要点

  • 在34+0周临床 cutoff 前入院者47%暴露于产前皮质类固醇,cutoff 后仅4.2%暴露。
  • 新生儿呼吸窘迫或院内死亡风险在34+0周突然升高,对应治疗保护效应(RR 0.69,95%CI 0.53-0.90)。
  • 对新生儿呼吸干预或院内死亡复合结局无明确证据支持或反对效应(RR 0.89,95%CI 0.70-1.13)。

核心结论

  • 研究结果提供证据支持产前皮质类固醇在双胎中预防不良新生儿呼吸结局的有效性。

研究设计与样本

  • 回归断点设计,应用于2008至2018年加拿大不列颠哥伦比亚省基于人群的出生登记数据。
  • 研究对象为31+0至36+6周入院分娩的双胎妊娠,共2524例妊娠(5035例活产双胎)。
  • 研究期间加拿大临床实践指南推荐对33+6周前即将早产者使用产前皮质类固醇。
  • 采用logistic模型比较临床 cutoff 前(产前皮质类固醇暴露概率较高)与 cutoff 后(暴露概率较低)入院分娩者的预测风险。

主要发现

  • 34+0周前入院者47%暴露于产前皮质类固醇,34+0周后入院者仅4.2%暴露。
  • 新生儿呼吸窘迫或院内死亡风险在34+0周突然升高,对应治疗保护效应(RR 0.69,95%CI 0.53-0.90;RD -12例/100例出生,95%CI -20至-4.1)。
  • 对新生儿呼吸干预或院内死亡复合结局无明确证据支持或反对效应(RR 0.89,95%CI 0.70-1.13;RD -4.2例/100例,95%CI -13至+4.2)。

关键数值与推荐

  • 主要结局为新生儿呼吸窘迫或院内死亡复合结局。
  • 次要结局为新生儿呼吸干预或院内死亡复合结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To estimate the effect of antenatal corticosteroids on newborn respiratory morbidity in twins. DESIGN: Regression discontinuity applied to population-based birth registry data. SETTING: British Columbia, Canada, 2008-2018. POPULATION: Twin pregnancies admitted for birth between 31+0 and 36+6 weeks of gestation. METHODS: During our study period, Canadian clinical practice guidelines recommended antenatal corticosteroid administration for imminent preterm birth up to 33+6 weeks. We used a logistic model to compare the predicted risks of our outcomes among pregnancies admitted for birth immediately before this clinical cut-point (higher probability of exposure to antenatal corticosteroids) versus immediately after it (lower probability). MAIN OUTCOME MEASURES: Our primary outcome was a composite of newborn respiratory distress or in-hospital death. Our secondary outcome was a composite of newborn respiratory intervention or in-hospital death. RESULTS: Among 2524 pregnancies (5035 liveborn twins), 47% of admissions before 34+0 weeks of gestation were exposed to antenatal corticosteroids but only 4.2% of admissions after this cut-point were exposed. The risk of newborn respiratory distress or in-hospital mortality increased abruptly at 34+0 weeks, corresponding to a protective effect of treatment (risk ratio [RR] 0.69, 95% CI 0.53-0.90; risk difference [RD] -12 cases per 100 births, 95% CI -20 to -4.1). There was no clear evidence for or against an effect on newborn respiratory intervention or in-hospital death (RR 0.89, 95% CI 0.70-1.13; RD -4.2 per 100, 95% CI -13 to +4.2). CONCLUSIONS: Our findings provide evidence for the effectiveness of antenatal corticosteroids in preventing adverse newborn respiratory outcomes in twins.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Socha PM, Harper S, Strumpf E, et al. Antenatal corticosteroids and newborn respiratory outcomes in twins: A regression discontinuity study. BJOG. 2024. PMID: 38221505. doi:10.1111/1471-0528.17754

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。